122 results about "High-density lipoprotein" patented technology

The invention belongs to the technical field of biological detection, and particularly relates to a biomarker combination and application thereof in IDH-1 gene mutation detection. The biomarker combination comprises one or more of the following lipid metabolites: a third component of high-density lipoprotein-triglyceride, a fourth component of high-density lipoprotein-triglyceride, high-density lipoprotein-triglyceride, lactic acid and sphingomyelin. Whether a glioblastoma patient carries IDH-1 gene mutation or not is judged through a plurality of biomarkers, the method has the advantages of being good in sensitivity and specificity, small in patient trauma, capable of overcoming individual differences and suitable for large-scale screening, and a new solution is provided for clinical patient diagnosis.

The invention provides an Auricularia auricula polysaccharide, its application and preparation method thereof, which belong to the technical field of improving polysaccharide. After being degreased, the Auricularia auricula is subjected to preliminary enzymolysis under the effect of helicase, is further subjected to deep enzymolysis under the effect of complex enzyme through synergetic ultrasound-assisted degradation and extraction with H2O2, and is subjected to mixed fermentation by Lactobacillus bulgaricus, Streptococcus thermophilus and Bifidobacterium longum, the obtained fermented Auricularia auricula polysaccharide is subjected to a phosphorylation reaction under the effect of a phosphorylation reagent, and after further deproteinization and decolorization, the obtained fermented Auricularia auricula polysaccharide is chelated with zinc salt to obtain a polysaccharide-zinc compound, and the amount of the extracted Auricularia auricula polysaccharide is improved. The finished product of the invention has the effects of reducing blood sugar and blood fat, regulating total cholesterol and effectively improving HDL cholesterol.

The invention relates to a cardiovascular disease risk assessment system and method. On the basis of fully considering the influence of dimension index information of kidney-related risk factors on the occurrence risk of cardiovascular diseases, heart and kidney metabolic indexes are integrated. And a mathematical model Fine-Gray is used for screening predictive factors by a step-by-step method. On the premise that traditional cardiovascular disease risk factors are reserved, in order to give consideration to the accuracy and easy generalization of risk assessment, prediction factors are simplified through strict calculation and derivation; the method is constructed based on a small amount of clinically ubiquitous detection index information such as age, sex, smoking or not, systolic pressure (SBP), fasting blood glucose (FBG), non-high density lipoprotein cholesterol (non-HDL-C) and estimated glomerular filtration rate (eGFR) as predictive factors. The method has the advantages of simplicity and convenience in operation, less required information and low professional requirement. Meanwhile, the risk of the outcome of various clinical cardiovascular diseases (including CVD, ASCVD and HF) can be evaluated at the same time, and the method can be suitable for various scenes such as primary medical care and clinical diagnosis and treatment.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention discloses a model for predicting the progression hepatic fibrosis risk of a WD long-term maintenance treatment patient and a design method thereof, and relates to the technical field of medical information, the prediction model comprises the following steps: an input module receives patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER), and the input module receives the patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER); the processing module obtains single scores corresponding to the seven independent risk factors, the single scores are added to obtain a total score, the prediction probability corresponding to the total score is the risk of the progression-stage hepatic fibrosis of the WD long-term maintenance treatment patient, and the prediction risk probability is output through the output module. The column diagram prediction model established by the invention has relatively high accuracy, and can be conveniently used for early recognition and risk prediction of progression-stage hepatic fibrosis of WD long-term maintenance treatment patients.

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

The present invention discloses a fusion protein, a high-density lipoprotein containing the fusion protein, and a bionic nano-drug, as well as preparation and application thereof. The fusion protein comprises an alpha-helical amphipathic polypeptide and a neuron targeting peptide. The high-density lipoprotein containing the fusion protein is used as a bionic nano-carrier to achieve brain-targeted delivery of the drug through intravenous administration, which saves manpower, material resources and financial resources compared with in situ administration to the brain, and significantly improves patient compliance.

The invention relates to the field of biological medicine, and discloses application of bionic high-density lipoprotein nanoparticles in preparation of drugs for targeting hepatitis virus receptor-1. The bionic high-density lipoprotein nanoparticle disclosed by the invention is composed of phospholipid and apolipoprotein mimetic peptide, wherein the apolipoprotein mimetic peptide is ApoA-I mimetic peptide. According to the invention, the bionic high-density lipoprotein nanoparticles can target hepatitis A virus receptor-1 for the first time, and can deliver drugs to cells of high-expression hepatitis A virus receptor-1 to play a therapeutic role. The biomimetic high-density lipoprotein nanoparticles co-loaded with anti-inflammatory and anti-fibrosis drugs can deliver the drugs to damaged renal tubules in a targeted manner especially for damaged renal tubule epithelial cells with selective high expression of KIM-1, so that kidney injuries are effectively relieved, chronic kidney diseases are treated, disease progression is relieved, and a new solution is provided for treatment of the chronic kidney diseases.

The invention discloses bifidobacterium adolescentis for relieving estrogen-related metabolic disorder and obesity and application thereof, and belongs to the technical field of microorganisms. The bifidobacterium adolescentis CCFM1506 screened by the invention can effectively improve ovariectomized individual estrogen disorder symptoms, obviously slow down the weight increase speed and weight increment of estrogen disorder individuals, increase the expression quantity of serum estradiol, CYP11A1 and ERalpha in adrenal gland and the high-density lipoprotein content in serum, reduce the total cholesterol and glucose level and improve the ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized ovariectomized abnormal glucose and lipid metabolism is adjusted; the invention has the advantages of simple preparation method and wide application prospect, can be used for preparing medicines for relieving or treating estrogen-related metabolic disorders and obesity, and can be used for preparing health-care products beneficial to controlling in-vivo fat and maintaining the health level of blood fat, and has obvious physiological effects and wide application prospects, and can be used for preparing the medicines for relieving or treating the estrogen-related metabolic disorders and obesity and preparing health-care products beneficial to controlling in-vivo fat and maintaining the health level of blood fat. A new thought and a new basis are provided for developing functional foods or medicines based on the probiotics.

The invention relates to the technical field of health care products, and provides a glycopeptide composition and related products and application thereof, and the glycopeptide composition comprises the following raw materials: wheat germs, herba epimedii, fermented bean products, flaxseeds and radix bupleuri. The glycoside peptide composition formed by combining the raw materials has a synergistic effect in the aspect of cardiovascular system protection. All the components interact with one another to jointly achieve the effects of reducing serum total cholesterol and triglyceride, improving high-density lipoprotein cholesterol, resisting oxidation, improving vascular functions and the like, and the composition has a remarkable protection effect on a cardiovascular system. Besides, the activity is enriched into the five raw materials to the maximum extent, so that the method has remarkable advantages in the aspects of production process and raw material cost reduction, and is beneficial to improving the production efficiency, ensuring the product quality and reducing the operation cost.

Provided are a method of assisting the detection of nonalcoholic steatohepatitis (NASH) and a method that is able to assist in determining the degree of progression of any condition associated with NASH, which are far less invasive than liver biopsy and include simple operations and are independent of the skills of technicians.The present invention provides a method of assisting the detection of nonalcoholic steatohepatitis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body. Also, the present invention provides a method of assisting in determining the degree of progression of at least one medical condition associated with nonalcoholic steatohepatitis, which medical condition(s) is(are) selected from the group consisting of fatty degeneration (steatosis), inflammation, ballooning degeneration, and fibrosis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body.

The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and / or therapeutic settings).

The present invention relates a method for maximizing the coronavirus killing activity of high-density lipoproteins, and a pharmaceutical composition for preventing or treating COVID-19. As identified by the present inventors, non-glycated normal high-density lipoproteins (HDLs) exhibit killing activity against coronavirus (SARS-Cov-2) that is superior to that of glycated HDLs, and thus a pharmaceutical composition for preventing and treating COVID-19, containing non-glycated native HDLs as an active ingredient, is provided. In addition, the present invention is useful since a method for maximizing the coronavirus killing activity by using an HDL glycation inhibitor, on the basis of the identification by the present inventors, can be provided and a method for screening for a pharmaceutical composition for preventing and treating COVID-19 by evaluating the degree of HDL glycosylation inhibition of candidate drugs can be provided.

The invention discloses a composition with an auxiliary blood fat reducing effect as well as a preparation method and application thereof, and relates to the technical field of medicines. In the composition disclosed by the invention, the hawthorn, the lotus leaf, the mulberry leaf and the algae oil are mutually matched for use and have a synergistic effect, so that the effects of remarkably reducing the body weight, reducing the content of low-density lipoprotein, the content of Apo-B and the content of GLU in blood and improving indexes of high-density lipoprotein and Apo-A1 are achieved. The composition is applied to preparation of the blood fat reducing medicine and / or health food, and the blood fat reducing effect is stable.

The invention discloses an anti-loss type bionic spherical high-density lipoprotein preparation as well as a preparation method and application thereof. The bionic spherical high-density lipoprotein preparation mainly comprises the following components: phospholipid, auxiliary lipid, apolipoprotein, an anti-loss functional module and a protein stabilizer, and the particle size of the preparation is 7-50nm. The bionic spherical high-density lipoprotein preparation disclosed by the invention is simple in preparation process, has the particle size and appearance close to those of natural high-density lipoprotein, has an enzyme-like antioxidant property, can protect own lipid and protein components in inflammation and oxidative stress pathological environments and maintain the structure stability, maintains the function of the high-density lipoprotein, and has a good application prospect. The medicine leakage can be reduced when the medicine is used as a medicine carrier. When being applied to treatment of inflammatory diseases such as sepsis, atherosclerosis and the like, the compound can remarkably reduce the ROS level in cells, change the phenotype of inflammatory cells and improve the survival rate of animals, and a feasible treatment scheme is provided for treatment of the inflammatory diseases.

The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and / or therapeutic settings).

The invention relates to the field of microorganisms, in particular to application of a microbial strain in preparation of a medicine for preventing or treating metabolic diseases, the microbial strain belongs to Enterococcus canini, and the metabolic diseases comprise diabetes, obesity, obesity-related diseases and metabolic syndromes. According to the present invention, with the application of the Enterococcus canintestini, the target spots GPR120 and MC4R for the treatment of obesity diabetes can be significantly activated; the weight, fasting blood glucose, area under a glucose tolerance curve and area under an insulin tolerance curve of obese mice can be reduced, the content of free fatty acid in plasma, total cholesterol in liver and low-density lipoprotein-cholesterol in liver can be reduced, and the content of glucagon-like peptide-1 in plasma and the content of high-density lipoprotein-cholesterol in liver can be increased.

The present invention relates to nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and / or therapeutic settings).

The invention relates to a method for constructing a preeclampsia prediction model by using clinical laboratory data and a related application thereof. Specifically, the preeclampsia risk prediction model is constructed based on a plurality of clinical indexes of pregnant women, a plurality of clinical laboratory data and insulin growth binding factor binding protein 1 and / or placental growth factors. The clinical laboratory data comprises leukocyte count and / or urine protein, and further comprises any one or combination of platelet count, monocyte proportion, glutamic-straw / glutamic-pyruvic transaminase ratio, glutamyltranspeptidase, uric acid and high-density lipoprotein. The constructed preeclampsia risk prediction model can provide a reliable implementation means for early prevention and early treatment of preeclampsia. Meanwhile, the sensitivity of the prediction model is 88.0% when the specificity of early eclampsia is 85.04% and the sensitivity of the prediction model is 62.5% when the specificity of late eclampsia is 85.04% in a complete independent verification set, and the detection performance of the prediction model is higher than that of the current detection performance.

Provided are molecular hooks that are capable of tethering a ribonucleic acid (RNA) of interest to a high-density lipoprotein (HDL) molecule. Also provided are methods of RNA delivery to cells and organisms using the molecular hooks of the present disclosure. Such methods provide several advantages including the ability to deliver the RNA of interest to tissues behind the blood-brain barrier, and not requiring extreme cold temperatures for storage or transport.

The invention relates to the technical field of anti-tumor bionic nanomaterials, and discloses a preparation method and application of tumor-bacterial membrane chimeric nanoparticles, and the preparation method comprises the following steps: carrying out rotary evaporation on dimyristoyl phosphatidylcholine and cholesterol oleate to obtain an HDL rotary evaporation film; mixing the tumor cell membrane with the bacterial membrane to obtain a tumor-bacterial mixed membrane; pre-mixing apolipoprotein ApoA-1 with the tumor-bacteria mixed membrane, and adding the mixed solution into a container containing an HDL rotary evaporation membrane for hydration and reconstruction to obtain a crude suspension; and carrying out ultrafiltration purification on the crude suspension to obtain the tumor-bacterial membrane chimeric nanoparticles. The tumor cell membrane and the bacterial membrane are co-loaded on the high-density lipoprotein, so that the two membrane components can be co-delivered to the dendritic cells to induce maturation of the dendritic cells, are accumulated in tumors and drainage lymph nodes in vivo, activate CD8 + T cell response and have an inhibition effect on tumor growth.

The present invention relates to a lipid-lowering peptide and its application. The sequence of the lipid-lowering peptide is: QIF (Gln-Ile-Phe). This lipid-lowering peptide not only has strong bile salt-binding ability, pancreatic lipase inhibitory effect and cholesterol esterase inhibitory effect, but also can effectively reduce the lipid content in cells, reduce the low-density lipoprotein content in cells and increase the high-density lipoprotein content in cells, thus having excellent lipid-lowering activity and can be widely used in lipid-lowering drugs.

The invention discloses a novel application of emodin and a high-density lipoprotein analogue in preparation of a medicine. The high-density lipoprotein analogue comprises apolipoprotein A-1 single mimetic peptide and natural phospholipid. The invention has the advantages of long-term stability and no immunogenicity and organ toxicity risk, thereby providing a clinically convertible solution for precise treatment of nerve injury.

The invention relates to the field of feed additives, and discloses a folium cortex eucommiae compound feed additive and a preparation method thereof, and the folium cortex eucommiae compound feed additive comprises the following components in parts by weight: 60-90 parts of fermented folium cortex eucommiae powder, 10-20 parts of cortex eucommiae seed meal, 1-5 parts of a traditional Chinese medicine extract, 2-10 parts of a microbial preparation, 5-10 parts of charcoal modified montmorillonite and 2-10 parts of a yeast cell wall extract. The folium cortex eucommiae compound feed additive is prepared by mixing the fermented folium cortex eucommiae with high-activity component content, the treated folium cortex eucommiae seed meal, the traditional Chinese medicine extract, the biochar modified montmorillonite and the yeast cell wall extract, and the folium cortex eucommiae compound feed additive prepared by the method has high-activity components; and under the condition that antibiotics and vaccines are not used, the production performance of the laying hens can be improved, the laying rate of the laying hens is increased, the soft and broken egg rate is reduced, animal health is maintained, the content of total cholesterol, triglyceride and low-density lipoprotein in blood is reduced, the content of high-density lipoprotein is increased, and the death rate of the laying hens is reduced.

The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and / or therapeutic settings).

The application discloses a composition for improving blood lipid metabolism, which comprises the following raw materials: sweet cinnamon powder, rhodiola powder, roxburgh rose powder and curcuma zedoaria powder. The preparation method of the composition for improving blood lipid metabolism comprises the following steps: screening the sweet cinnamon powder, the rhodiola powder, the roxburgh rose powder and the curcuma zedoaria powder respectively, mixing them uniformly to obtain mixed powder; adding sterile deionized water into the mixed powder to obtain a mixed solution; adding a complex enzyme into the mixed solution for enzymolysis; after the enzymolysis is completed, the enzyme is inactivated, filtration is conducted, and the filtrate is freeze-dried to obtain the composition for improving blood lipid metabolism. The plant powder is subjected to mixed enzymolysis through multiple enzymes, the natural active substances in the plant powder are enriched, and the types of the enzymolysis products are enriched, so that the total cholesterol, the triglyceride and the low-density lipoprotein content in blood can be reduced, and the high-density lipoprotein content in blood can be increased.

Provided are molecular hooks that are capable of tethering a protein of interest to a high-density lipoprotein (HDL) molecule. Also provided are methods of intracellular protein delivery to cells and organisms using the molecular hooks of the present disclosure. Such methods provide several advantages including the ability to intracellularly deliver the protein of interest to tissues behind the blood-brain barrier, and not requiring extreme cold temperatures for storage or transport.

The invention relates to the field of intelligent medical treatment, in particular to a pregnancy disease risk prediction method and device based on biochemical indexes and a program product. Comprising the following steps: S1, acquiring serum biochemical index data of a pregnant woman; s2, comparing the serum biochemical indexes with a preset threshold value; the serum biochemical indexes include aspartate aminotransferase, total protein, albumin, lactic dehydrogenase, alkaline phosphatase, total bile acid, creatine kinase, blood sugar, urea nitrogen, uric acid, creatinine, glomerular filtration rate, potassium, chlorine, total calcium, serum magnesium, inorganic phosphorus, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and homocysteine. When one or more of the myoglobin, the hypersensitive troponin I, the prealbumin, the cystatin C and the creatine kinase isoenzyme MB are abnormal, judging that the pregnancy eclampsia exists. The method is simple, convenient and rapid to operate and low in cost, can be clinically popularized to predict the health state of the pregnant woman on a large scale, and has good clinical value.

The present invention discloses the preparation of Sipunculus nudus hypoglycemic peptide and its application in the preparation of drugs for regulating blood glucose and blood lipids in type 2 diabetes, belonging to the field of biomedical technology. The Sipunculus nudus polypeptide provided by the present invention can significantly reduce the blood glucose concentration of T2DM, regulate the level of insulin resistance, inhibit the levels of triglyceride and low-density lipoprotein cholesterol in the serum of T2DM, increase the level of high-density lipoprotein cholesterol, and at the same time has a protective effect on the pathological changes of pancreatic tissue. In addition, administration of Sipunculus nudus polypeptide can increase the activity of SOD in the serum and inhibit the expression of malondialdehyde, a lipid peroxidation marker. The Sipunculus nudus polypeptide can significantly improve the abnormal blood glucose and blood lipids in type 2 diabetes, and has no toxicity or side effects on animals and will not accumulate in animals. Therefore, the Sipunculus nudus polypeptide can be used to prepare drugs or foods for regulating blood glucose and blood lipids in type 2 diabetes.

A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein phospholipase and / or sphingomyelinase is / are allowed to act on a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.